5-FU Added to Drug Shortage List

This morning the FDA added fluorouracil to its drug shortage list. The American Society of Healthcare Pharmacists (ASHP) has also reported a shortage of fluorouracil (5-FU), a common backbone drug for colorectal cancer chemotherapy. Two manufacturers have some doses of the drug on intermittent back order and are shipping it as it becomes available.  A third…  Read More

DNA Mismatch Repair and 5-FU: What's the Connection?

Some colon cancer patients don’t benefit from treatment with 5-FU based chemotherapy and may even have worse outcomes than if they no chemo at all. Of every 100 people with colon cancer, about 15 will have cancers that arise when mistakes in DNA during cell division are not caught and fixed.  Scientists call this defective mismatch…  Read More

XELOX Beats 5-FU with Fewer Recurrences

A combination of Xeloda and Eloxatin (XELOX) was better than standard 5-FU and leucovorin chemotherapy in reducing recurrences of stage III colon cancer after surgery.  Significantly more patients receiving XELOX were alive without cancer three years after treatment began. Roche announced results of a Phase III clinical trial that compared XELOX chemotherapy to bolus 5-FU and…  Read More

Comparing 5-FU or Capecitabine Combined with Oxaliplatin

Infusional 5-FU or oral Xeloda® (capecitabine) are two different drugs that can be combined with Eloxatin® (oxaliplatin) to treat colorectal cancer that has spread.  Six different randomized clinical trials have compared the two approaches. Researchers analyzed a pool of all six trials to find out if one approach is better than the other. While they found…  Read More

KRAS Status Doesn't Impact Treatment with 5-FU Alone

While researchers have found that colorectal cancer tumors that have mutated KRAS genes don’t respond to treatment with EFGR inhibitors Erbitux®(cetuximab) and Vectibix™(panitumumab), is the same thing true for other drugs? 5-FU (fluorouracil) is the backbone of most colorectal cancer treatment, given alone or in combination with other drugs.  What does KRAS status mean when 5-FU…  Read More

Switching from 5FU to Xeloda Can Cause Significant Side Effects

An immediate switch from 5-FU treatment to Xeloda® (capecitabine) for stage III colon cancer caused so much toxicity that a trial designed to test patient preferences for treatment had to be stopped. Patients in the Patient Preference in Adjuvant Therapy (PACT) trial who switched after 6 weeks from weekly 5-FU with leucovorin to oral capecitabine experienced…  Read More